The Role 10 Gut Hormones in Appetite Regulation
Gut hormones play a critical role in relaying signals of nutritional and energy status from the gut to the central nervous system, in order to regulate food intake. Cholecystokinin, peptide YY, pancreatic polypeptide, glucagon-like peptide-1, and oxyntomodulin act through distinct yet synergistic mechanisms to suppress appetite, whereas ghrelin stimulates food intake. There is role of gut hormones in the regulation of food intake and body weight.
Appetite regulation and adequate eating behavior are crucial for survival. To begin and to stop eating is a complex process. Appetite regulation, perception of hunger and satiety, eating behavior, and food preferences are in great part determined by genetic factors. Therefore, if tasty and energy-rich food is freely available in potentially unlimited quantities, overeating may occur due to insufficient defense mechanisms. Pleasure-seeking and hedonic responses to food intake are mediated by humoral substances, for example, endorphins, dopamine, and endocannabinoids.
More than 30 gut hormone genes are known to be expressed, and more than 100 bioactive peptides are distributed in the gastrointestinal tract, which is thus regarded as the largest endocrine organ in the body. Meal anticipation and the presence of food in the upper gastrointestinal tract stimulate the release of gut hormones and neurotransmitters from the gut. These neurohumoral signals are involved in the initiation and maintenance of food intake as well as termination of meals. The satiating effect of stomach distension is revealed by observing that infusion of either saline or nutrients into the rat stomach results in same reduction in food intake
The Role 10 Gut Hormones in Appetite Regulation
- PP-Fold Protein The PP-fold family consists of neuropeptide Y (NPY), peptide YY (PYY), and pancreatic polypeptide (PP). PYY and PP are secreted from gastrointestinal tract, whereas NPY is predominantly distributed within central nervous system . The members of PP-fold family act via G protein-coupled receptors: Y1, Y2, Y4, Y5, and Y6
- Peptide Tyrosine Tyrosine (PYY) PYY was first isolated as a 36-amino acid peptide from porcine upper small intestine . PYY is released by L cells of the distal gut. There are two circulating forms of PYY: PYY (1–36) and PYY (3–36). PYY (3–36), the major circulating form, is produced by cleavage of the N-terminal Tyrosine-Proline residues from PYY (1–36) by the enzyme dipeptidyl-peptidase IV (DPPIV) . PYY (1–36) has affinity to all Y receptors, while PYY (3–36) binds with highest affinity to the hypothalamic Y2 receptor, suppressing food intake. Circulating PYY concentrations are low in fasted state and rise rapidly following a meal with a peak at 1-2 hours and remain elevated for several hours. Ingestion of fat results in greater release of PYY than observed with ingestion of carbohydrate or protein meals with a similar calorie content. Peripheral PYY administration shows a decrease in food intake and body weight gain in rats. In both lean and obese humans, intravenous injection of PYY reduces appetite and food intake, suggesting that, unlike leptin, the sensitivity of PYY is preserved in obese subjects. PYY levels are found to be elevated in patients with gastrointestinal disorders including inflammatory bowel disease and steatorrhea
In addition to its effect on food intake, PYY may regulate energy expenditure, delay gastric emptying, and reduce acid secretion. In obese subjects circulating PYY levels are low, and PYY levels are reported to be higher in patients with anorexia nervosa when compared with control subjects. Studies of circulating levels of PYY in obese and lean people have yielded conflicting results. However a blunted postprandial rise in PYY is observed in obese people, which suggests its association with impaired satiety . The anorectic effects of PYY (3–36) may be mediated centrally via a direct action in the ARC, through an indirect action involving the vagus and brainstem, or by a combination of both pathways. Peripheral administration of PYY (3–36) increases c-fos expression (a marker of neuronal activation) in the ARC, and direct injection of PYY (3–36) into the ARC inhibits food intake. This effect is most likely mediated through the Y2 receptor since the anorectic effect of peripheral PYY (3–36) administration is blocked in Y2 receptor-null mice and intra-arcuate injection of a Y2 receptor selective agonist also reduces food intake. Although there have been conflicting results , the importance of vagal-brainstem signalling to the actions of PYY on food intake is suggested by observing that bilateral subdiaphragmatic vagotomy and brainstem-hypothalamic pathway transectioning abolish the anorectic effect of peripheral PYY (3–36) administration in rats.
In contrast to peripheral and intra-arcuate PYY (3–36) administration, PYY (3–36) results in an increase in food intake when administered directly into the third ventricle of the brain or directly into the paraventricular nucleus (PVN) . This apparently confusing observation may be explained by considering that such effects might be endogenously mediated by the CNS-distributed peptide, NPY, through an action on Y1 receptor and Y5 receptors .
PYY may also act in areas of the brain other than the hypothalamus and brainstem. Batterham et al. suggested that PYY (3–36) infusion modulates neural activity within corticolimbic and higher cortical brain using functional magnetic resonance imaging. Under conditions of high circulating PYY (3–36) designed to mimic the postprandial state, changes in neural activity within the caudolateral orbital frontal cortex predicted subsequent feeding behaviour. By contrast, hypothalamic activation correlated with food intake under conditions of low circulating PYY (3–36).
- Pancreatic Polypeptide (PP). PP is secreted from PP cells in the pancreatic islets of Langerhans. PP appears to reduce food intake directly through the Y4 receptor in the brainstem and hypothalamus. The anorectic effects of PP are abolished by vagotomy in rodents, suggesting that PP may also act via the vagus nerve to reduce food intake . Y4 receptor expression is found in the AP, NTS, DVN, ARC, and PVN . An autoradiography study also identified saturable PP binding sites at the interpeduncular nucleus, AP, NTS, and DVN, thus suggesting the brainstem as the major site of action for PP. Like PYY, differential effects on food intake are observed following PP injection, depending on the route of administration. In contrast to the anorectic effects observed with peripheral PP administration, its central administration stimulates food intake. These differential effects may be explained by activation of distinct receptor populations, although the exact mechanism is not yet clear. Circulating PP concentrations rise after a meal in proportion to the calorific load. Although reported differences in circulating levels of PP between lean and obese people have been conflicting , some studies have demonstrated significantly reduced levels in obese subjects. Levels of PP are elevated after a test meal in anorexia . Patients with Prader-Willi syndrome (PWS) have been reported to show reduced PP release both basally and postprandially when compared with age- and weight-matched control subjects.
The anorectic effects of PP have been demonstrated in a number of experimental models. In mice, acute and chronic peripheral administration of PP reduces food intake. In leptin-deficient ob/ob mice, repeated intraperitoneal injection of PP decreases body weight gain and ameliorates insulin resistance and hyperlipidaemia. Furthermore, transgenic mice overexpressing PP are lean and demonstrate reduced food intake compared with wild-type controls . In normal-weight human subjects, intravenous infusion of PP results in a 25% reduction in 24-h food intake. Furthermore twice-daily infusion of PP in volunteers with PWS caused a 12% reduction in food intake
- Ghrelin Ghrelin is the only known orexigenic gut hormone and was identified as an endogenous ligand for the growth hormone secretagogue receptor (GHS-R) in rat stomach. Lower levels of ghrelin are also localized to the hypothalamic ARC. Levels of circulating ghrelin increase preprandially and fall rapidly in the postprandial period. Both central and peripheral administrations of ghrelin increase food intake and body weight with a reduction in fat utilisation in rodents. In human, negative correlations between circulating ghrelin levels and body mass index are found. Fasting plasma levels of ghrelin are high in patients with anorexia nervosa and in subjects with diet-induced weight loss. By contrast, obese subjects display a less marked drop in plasma ghrelin after meal injection/ Plasma ghrelin levels are elevated in cachectic patients with heart failure as compared with noncachectic patients with heart failure and control subjects. Furthermore elevated circulating ghrelin levels are observed in patients with PWS compared with individuals with nonsyndromic forms of obesity. Dysregulation of ghrelin secretion is also implicated in the mechanism through which sleep disturbance contributes to obesity. Subjects with short sleep duration have elevated ghrelin levels, reduced leptin, and high body mass index compared with subjects with normal sleep duration. Evidence suggests that ghrelin mediates its orexigenic action via stimulation of NPY/AgRP coexpressing neurons within the ARC of hypothalamus. Peripheral administration of ghrelin increases c-fos expression in ARC NPY/AgRP neurons, and ablation of both AgRP and NPY neurons completely abolishes the orexigenic effect of ghrelin . Brainstem and vagus nerve may also contribute to the effects of ghrelin on food intake. Intracerebroventricular injection of ghrelin induces c-fos expression in NTS and AP. GHS-R is expressed in the vagus nerve. Furthermore blockade of gastric vagal afferents in rats abolishes ghrelin-induced feeding and prevents the ghrelin-induced rise in c-fos expression within the ARC. Ghrelin may promote food intake in part by enhancing the hedonic responses to food cues. The recent study by Malik et al. using functional magnetic resonance imaging during exposure to food pictures revealed increased activation in the amygdala, orbitofrontal cortex, anterior insula, and striatum, during intravenous infusion of ghrelin. Furthermore the effects of ghrelin on the response of amygdala and orbitofrontal cortex were correlated with self-rated hunger ratings.
- Cholecystokinin CCK was the first gut hormone found to play a role in food intake. CCK is secreted postprandially by the I cell of the small intestine into circulation , with a short plasma half-life of a few minutes. Plasma CCK levels rise within 15 minutes after meals. CCK is reported to reduce food intake in human and rodents. There are two CCK receptor subtypes; CCK1 and CCK2 receptors, previously classified as CCK A and CCK B. The anorectic action of CCK appears to be mostly mediated via CCK1 receptors on the vagal nerve. CCK 1 and 2 receptors are widely distributed in brain including the brainstem and hypothalamus. Intermittent prandial CCK infusion reduces meal size in rats but provokes a compensatory increase in meal frequency. In addition, a 2-week continuous intraperitoneal infusion of CCK failed to suppress food intake at any time point
- Peripheral Adiposity Signals: Insulin and Leptin Adiposity signals are involved in the long-term regulation of energy balance, while gut peptides modulate food intake on a meal-by-meal basis. Circulating levels of insulin and leptin are positively correlated with adipose tissue mass within the body and are implicated in the long-term regulation of energy balance. Insulin is synthesized in the β cells of the pancreas and secreted rapidly after a meal, with well-characterised hypoglycaemic effects. However intracerebroventricular administration of insulin also results in a dose-dependent suppression of food intake and body weight gain in baboons and rodents. Insulin may therefore have an anorectic action in addition to its hypoglycaemic effects. Leptin is secreted by adipocytes with circulating levels proportional to fat mass with a diurnal and pulsatile pattern, peaking at night. Leptin administration alleviates the hyperphagia associated with congenital leptin deficiency. However obese subjects are resistant to leptin, which may account for its lack of effectiveness in such individuals
- Proglucagon-Derived Peptides GLP-1, GLP-2, oxyntomodulin (OXM), and glucagon are proglucagon-derived peptides. Proglucagon is expressed in the pancreas, L-cells of the small intestine, and in the NTS of the brainstem [64, 65]. Glucagon is produced in the pancreas, whereas OXM, GLP-1, and GLP-2 are the major products in the brain and intestine
- Glucagon-Like Peptide-1 GLP-1 is cosecreted with PYY from L cells in the intestine in response to nutrient intake. Enzymatic degradation by DPPIV and renal clearance rapidly inactivate and remove GLP-1 from plasma circulation, respectively [67, 68], thus accounting for its short plasma half-life of 1-2 minutes . GLP-1 has two biologically active forms, GLP-1 (7–37) and GLP-1 (7–36) amide, the latter being the major circulating form in humans. GLP-1 exerts its effect at the GLP-1R to stimulate adenylyl cyclase activity and thereby cAMP production. GLP-1R is widely distributed particularly in the brain, GI tract, and pancreas. Circulating GLP-1 levels rise after a meal and fall in the fasted state. Recent evidence also suggests that levels rise in anticipation of a meal. GLP-1 reduces food intake, suppresses glucagon secretion, and delays gastric emptying. Intravenous infusion of GLP-1 results in a dose-dependent reduction of food intake in both normal weight and obese subjects ; however obese subjects have a blunted postprandial GLP-1 response compared to lean subjects. GLP-1 possesses a potent incretin effect in addition to its anorectic action; it stimulates insulin secretion in a glucose-dependent manner following ingestion of carbohydrate. Continuous subcutaneous infusion of GLP-1 to patients with type 2 diabetes for 6 weeks reduces appetite, body weight and improves glycaemic control. Exendin-4, a naturally occurring peptide from the saliva of the Gila monster lizard, is a DPPIV-resistant GLP-1R agonist. Exendin-4 (exenatide, Byetta) has been approved for type 2 diabetes in conjunction with either metformin, a sulphonylurea, or both drugs. Twice-daily subcutaneous injection of exendin-4 to type 2 diabetes patients failing to achieve glycaemic control with maximal doses of metformin improves glycaemic control and decreases body weight. Once-weekly subcutaneous injection of a long-acting exenatide preparation and once-daily subcutaneous injection of the GLP-1 analogue called liraglutide demonstrate greater improvements in glycaemic control than twice-daily exenatide administration. GLP-1 possesses trophic effects on pancreatic beta cells in animal models. Most recently, GLP-1 and exendin-4 have been shown to promote cellular growth and reduce apoptosis in nervous tissues. GLP-1 receptor stimulation has been shown to have neuroprotective effect in models of Parkinson’s disease, Alzheimer’s disease, cerebrovascular stroke, and peripheral neuropathy. Further work is needed to determine if GLP-1 analogues could be potential novel therapies for patients with these neurological and neurodegenerative diseases.
- Glucagon-Like Peptide-2 GLP-2 is released from enteroendocrine cells in a nutrient-dependent manner, like GLP-1. Acute or chronic administration with GLP-2 has no effect on food intake in either rodents or humans. However, GLP-2 has an intestinal trophic effect and chronic subcutaneous administration of GLP-2 stimulates crypt cell proliferation. As such, GLP-2 analogues have been developed for use in patients with inflammatory bowel disease. In addition, some studies have demonstrated a reduction in gastric emptying in humans by GLP-2, although the effect is not as potent as GLP-1.
- Oxyntomodulin OXM is another product of the proglucagon gene and is released from L-cells of the intestine in response to ingested food and in proportion to caloric intake. Administration of OXM reduces food intake and increases energy expenditure in both rodents and humans. The anorectic effect of OXM is blocked by the GLP-1R antagonist exendin 9–39 and is abolished in GLP-1R null mice; this suggests that OXM mediates its effects via the GLP-1R. However OXM has relatively low in vitro affinity for the GLP-1R which is 50 fold lower than the affinity of GLP-1 for GLP1R. This raises the possibility that a further receptor through which OXM mediates its anorectic effect has yet to be identified. Indeed, several actions of OXM appear to be independent of the GLP-1R. For example, the cardiovascular effects of OXM are preserved in GLP-1R knockout mice. Like GLP-1, OXM is inactivated by DPPIV; hence OXM analogues resistant to DPPIV degradation are being developed as potential obesity treatments
- Keisuke Suzuki, Channa N. Jayasena, and Stephen R. Bloom. The Gut Hormones in Appetite Regulation. Journal of ObesityVolume 2011 (2011), Article ID 528401, 10
- Suzuki K, Simpson KA, Minnion JS, et al. The role of gut hormones and the hypothalamus in appetite regulation. Endocr J 2010; 57:359–372.
PICKY EATERS AND GROW UP CLINIC For Children, Teen and Adult(Klinik Khusus Sulit Makan dan Gangguan Berat Badan) GRoW UP CLINIC JAKARTAYudhasmara Foundation Inspirasi Orangtua Cerdas, Tumbuhkan Anak Semakin Sehat, Kuat dan Pintar
- GRoW UP CLINIC I Jl Taman Bendungan Asahan 5 Bendungan Hilir Jakarta Pusat 10210, phone (021) 5703646 – 44466102
- GRoW UP CLINIC II MENTENG SQUARE Jl Matraman 30 Jakarta Pusat 10430, phone (021) 44466103 – 97730777
- email : email@example.com firstname.lastname@example.org
WORKING TOGETHER SUPPORT TO THE HEALTH OF ALL BY CLINICAL, RESEARCH AND EDUCATIONS. Advancing of the future pediatric and future parenting to optimalized physical, mental and social health and well being for fetal, newborn, infant, children, adolescents and young adult
Clinical – Editor in Chief :
Information on this web site is provided for informational purposes only and is not a substitute for professional medical advice. You should not use the information on this web site for diagnosing or treating a medical or health condition. You should carefully read all product packaging. If you have or suspect you have a medical problem, promptly contact your professional healthcare provider
Copyright © 2012, Picky Eaters and Grow Up Clinic, Information Education Network. All rights reserved